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The acyclic pyrimidine nucleoside phosphonate (ANP)
phosphonylmethoxyethoxydiaminopyrimidine (PMEO-DA-
Pym) differs from other ANPs in that the aliphatic alkyloxy
linker is bound to the C-6 of the 2,4-diaminopyrimidine base
through an ether bond, instead of the traditional alkyl linkage to
theN-1 orN-9 of the pyrimidine or purine base. In this study, we
have analyzed the molecular interactions between PMEO-DA-
Pym-diphosphate (PMEO-DAPym-pp) and the active sites of
wild-type (WT) and drug-resistant HIV-1 reverse transcriptase
(RT). Pre-steady-state kinetic analyses revealed that PMEO-
DAPym-pp is a good substrate for WT HIV-1 RT: its catalytic
efficiency of incorporation (kpol/Kd) is only 2- to 3-fold less than
that of the corresponding prototype purine nucleotide analogs
PMEA-pp or (R)PMPA-pp. HIV-1 RT recognizes PMEO-DA-
Pym-pp as a purine base instead of a pyrimidine base and incor-
porates it opposite to thymine (in DNA) or uracil (in RNA).
Molecular modeling demonstrates that PMEO-DAPym-pp fits
into the active site ofHIV-1RTwithout significant perturbation
of key amino acid residues and mimics an open incomplete
purine ring that allows the canonicalWatson-Crick base pairing
to be maintained. PMEO-DAPym-pp is incorporated more effi-
ciently than (R)PMPA-pp by mutant K65R HIV-1 RT and is not
as efficiently excised as (R)PMPAbyHIV-1RTcontaining thymi-
dine analog mutations. Overall, the data revealed that PMEO-
DAPym represents the prototype compound of a novel class of
pyrimidine acyclic nucleosidephosphonates that are recognizedas
a purine nucleotide and should form the rational basis for the
design and development of novel purine nucleo(s)(t)ide mimetics
as potential antiviral or antimetabolic agents.
Acyclic nucleoside phosphonates (ANPs)2 are nucleotide
analogs that are characterized by the presence of a phosphonate
group linked to a pyrimidine or purine base through an ali-
phatic linker (1). ANPs can be functionally divided into differ-
ent structural subclasses (see Fig. 1) that include: (i) the phos-
phonylmethoxyethyl (PME) derivatives (e.g. PMEA (adefovir));
(ii) the phosphonylmethoxypropyl (PMP) derivatives (e.g.
(R)PMPA (tenofovir) and (S)FPMPA); and (iii) the hy-
droxyphosphonylmethoxypropyl (HPMP) derivatives (e.g.
(S)HPMPA and (S)HPMPC (cidofovir)) (1–5). Analogs of each
subclass are endowedwith a characteristic and specific antiviral
activity spectrum (6). For example, the PME-purine derivatives
are active against several DNA viruses (e.g. herpesviruses, pox-
viruses, and hepatitis B virus) and retroviruses (e.g. HIV-1),
whereas the PMP-purine derivatives display antiviral activity
against retroviruses and hepatitis B virus only. The HPMP-pu-
rine derivatives are active against a broad variety of DNA
viruses (e.g. herpesviruses, poxviruses, and adenoviruses),
whereas the cytosine derivative (S)HPMPC represents the sole
HPMP-pyrimidine derivative that shows selective activity
against cytomegalovirus and poxviruses. Interestingly, the
PME- and PMP-pyrimidine derivatives do not exhibit antiviral
activity. Thus, minor structural modifications in the side chain
and also the identity of the base have a marked impact on
the ANP antiviral activity spectrum. All of the ANPs described
above are metabolized to a diphosphate form in the cell and act
as competitive inhibitors (alternative substrates) of the virus-
encoded DNA polymerase (4, 7–11). The ANP-diphosphate
binds to the active site of the viral polymerase and competes
with the corresponding natural nucleotide (e.g. dATP for
(S)HPMPA, PMEA, (S)FPMPA and (R)PMPA, and dCTP for
(S)HPMPC) for subsequent incorporation into the growing
DNA chain.
Recently, a new structural subclass of ANP, the acyclic phos-
phonylmethoxyethoxy- and phosphonylmethoxypropoxydi-
aminopyrimidines (designated PMEO- and PMPO-DAPym)
derivatives, was identified (12–15). These ANPs differ from the
other subclasses by the presence of an aliphatic alkyloxy linker
bound to the C-6 of a 2,4-diaminopyrimidine base through an
ether bond instead of the traditional alkyl linker bond to the
N-1 of a pyrimidine or the N-9 of a purine (Figs. 1 and 2).
Interestingly, and in contrast to the PME- and PMP-pyrimi-
dines, the PMEO- and PMPO-pyrimidine ANP derivatives
exhibit pronounced activity against both retroviruses and hep-
atitis B virus (16). Of further interest, these analogs display an
antiviral activity spectrum that is similar to the PME- andPMP-
purines. Therefore, it was speculated that there was structural
similarity between the 2,6-diaminopurine (DAP) PME-deriva-
tive (PMEDAP) and the PMEO-DAPym derivatives (12). This
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was supported by molecular modeling and superimposition of
their optimized three-dimensional structures, which demon-
strated that the 2,4-diamino-substituted pyrimidine could be
regarded as an open-ring analog of the purine system in the
2,6-diaminopurine ANPs (Fig. 2) (16).
In this study, we have analyzed the molecular interactions
between PMEO-DAPym diphosphate (PMEO-DAPym-pp)
and the active site of HIV-1 reverse transcriptase (RT, EC
2.7.7.49) using both steady-state and pre-steady-state kinetic
analyses. The in vitro activity of PMEO-DAPym-pp against
wild-type (WT) and drug-resistant recombinant purified
HIV-1RTwas also comparedwith the PME-purine (e.g.PMEA)
and PMP-purine (e.g. (R)PMPA) analogs. Importantly, we show
for the first time that the acyclic pyrimidine nucleoside phos-
phonate derivative PMEO-DAPym-pp is incorporated into the
growing DNA chain byHIV-1 RT as a purine nucleotide analog
but not as a pyrimidine nucleotide analog. Therefore, PMEO-
pyrimidine derivatives successfully mislead the viral DNA
polymerase and act as purine nucleotide mimetics. Also, we
obtained kinetic evidence that PMEO-DAPymmayhave a ther-
apeutic edge over (R)PMPA (tenofovir) in terms of its level of
phenotypic drug resistance. The identification of suchmodified
pyrimidine analogs opens new perspectives for developing
novel types of such ambiguous pyrimidine nucleosides or
nucleotides with antiviral or antimetabolic potential.
EXPERIMENTAL PROCEDURES
Reagents—The WT HIV-1 RT used in the steady-state
kinetic experiments that utilized homopolymeric template/
primers (T/Ps) was derived from anHIV-1 (SF2 strain) pol gene
fragment coding for theRT (Pro156–Leu715). The stock solution
was 0.36mg/ml. TheWT,K65R,K70E,M184V,M41L/L210W/
T215Y (TAM41), and D67N/K70R/T215F/K219Q (TAM67)
HIV-1 RTs used in the steady-state and pre-steady-state kinetic
experiments that utilized heteropolymeric T/Ps were purified
as described previously (17, 18). The protein concentration of
these enzymes was determined spectrophotometrically at 280
nm using an extinction coefficient (280) of 260,450 M1 cm1
and by Bradford protein assays (Sigma-Aldrich). The RNA- and
DNA-dependent DNA polymerase activities of the purifiedWT
and mutant enzymes were essentially identical (data not shown).
(R)PMPA diphosphate ((R)PMPA-pp) and PMEA diphosphate
(PMEA-pp) were purchased from Moravek Biohemicals (Brea,
CA). PMEO-DAPym-ppwas synthesized andprovidedbyA.Holy´
(Prague, Czech Republic). ATP, dNTPs, and ddNTPs were pur-
chased from Amersham Biosciences, and [-32P]ATP was
acquired from PerkinElmer Life Sciences. RNA andDNA hetero-
polymeric oligonucleotides were synthesized by IDT (Coralville,
IA). The templates poly(rC), poly(rA), poly(rI), and poly(rU) as
well as the primers oligo(dG)12–18, oligo(dT)12–18, oligo(dC)12–18,
and oligo(dA)12–18 were from Amersham Biosciences. The hom-
polymeric T/P substrates poly(rC)/oligo(dG), poly(rA)/oligo(dT),
poly(rI)/oligo(dC), and poly(rU)/oligo(dA) were prepared bymix-
ing 0.15mM template with an equal volume of 0.0375mM primer.
Steady-state Assays Using Homopolymeric T/Ps—Reactions
(50 l in volume) were carried out in a 50 mM Tris-HC1 (pH
7.8) buffer that contained 5 mM dithiothreitol, 300 mM gluta-
thione, 0.5 mM EDTA, 150 mM KC1, 5 mM MgC12, or 5 mM
MnCl2, 1.25 g of bovine serum albumin, 0.06% Triton X-100,
an appropriate concentration of [3H]dTTP, [3H]dGTP,
[3H]dCTP, or [3H]dATP (2 Ci/assay), varying concentrations
of ANP analog, and a fixed concentration of poly(rA)/oligo(dT)
(0.015 mM), poly(rC)/oligo(dG) (0.1 mM), poly(rI)/oligo(dC)
(0.015 mM), or poly(rU)/oligo(dA) (0.015 mM). Reactions were
initiated by the addition of 1 l of RT and were incubated for 15
min at 37 °C. Reactions were then terminated by the addition of
100l of 150g/ml calf thymusDNA, 2ml of 0.1MNa4P2O7 (in 1
M HCl), and 2 ml of 10% (v/v) trichloroacetic acid. The solutions
were kept on ice for 30min afterwhich the acid-insolublematerial
waswashedandanalyzed for radioactivity. For50%inhibitorycon-
centration (IC50) determinations, fixed concentrations of 1.25M
[3H]dTTP, 2.5 M [3H]dGTP, 1.75 M [3H]dATP, or 2.5 M
[3H]dCTPwereused.For theKideterminationswithrespect to the
natural substrates, a fixed concentration of T/P was used (as indi-
cated above). For theKi determinations with respect to T/P, vary-
ing concentrations of the T/P were used in the presence of a fixed
concentration of 1.25 M [3H]dTTP, 2.5 M [3H]dGTP, 1.75 M
[3H]dATP, or 2.5 M [3H]dCTP. The steady-state kinetic con-
stantsKi andKmwere determined by linear regression using dou-
ble-reciprocal Lineweaver-Burke plots.
Steady-state Assays Using Heteropolymeric T/P—The ability
of PMEO-DAPym-pp to inhibit HIV-1 RT DNA synthesis was
also evaluated using heteropolymeric DNA/DNA and RNA/
FIGURE 1. Structures of PME (PMEA), PMP ((R)PMPA), and HPMP
((S)HPMPA, (S)FPMPA, and (S)HPMPC) ANP derivatives and the corre-
sponding PMEO-, (R)PMPO-, (S)HPMPO-, and (S)FPMPO-diaminopyrimi-
dines (DAPym).
FIGURE 2. Structural similarity between the PME-diaminopurine (DAP)
derivative and PMEO-DAPym.
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DNA T/Ps. Briefly, reactions were carried out in 50 mM Tris
(pH 7.5), 50 mM KCl, 10 mM MgCl2 containing 20 nM T/P, 0.5
M each dNTP, and various concentrations of PMEO-DA-
Pym-pp (0–40 M). The sequences of the T/P substrates are
provided in Fig. 4, and the DNA primers were 5-radiolabeled
with [-32P]ATP as described previously (19). Reactions were
initiated by the addition of 200 nM WT RT, incubated for 10
min at 37 °C, and then quenched using 20 l of gel-loading
buffer (98% deionized formamide containing 1 mg/ml each of
bromphenol blue and xylene cyanol). Control reactions
included the addition of either (R)PMPA-pp or PMEA-pp.
Samples were then denatured at 95 °C for 10 min, and polym-
erization products were separated from substrates by denatur-
ing gel electrophoresis using 14% acrylamide containing 7 M
urea. Gels were analyzed using phosphorimaging with a GS525
Molecular Imager and Quantity One Software (Bio-Rad). The
concentration of ANP-diphosphate required to inhibit the for-
mation of final product by 50% was calculated using non-linear
regression from at least three independent experiments. The
amount of final product was quantified by densitometric anal-
ysis using Quantity One Software.
Pre-steady-state Assays—Arapid quench instrument (Kintek
RQF-3 instrument, Kintek Corp., Clarence, PA) was used for
pre-steady-state experiments with reaction times ranging from
20ms to 60 s. The typical experiment was performed at 37 °C in
50mMTris-HCl (pH 7.5) containing 50mMKCl, 10mMMgCl2,
and varying concentrations of nucleotide. All concentrations
reported refer to the final concentrations after mixing. HIV-1
RT (200 nM) was preincubated with 20 nM T/P substrate, prior
to rapid mixing with nucleotide and divalent metal ions to ini-
tiate the reaction that was quenched with 0.5 M EDTA. The
sequences of the template and 5-radiolabeled primer were 5-
CTCAGACCCTTTTAGTCAGAATGGAAATTCTCTAGC-
AGTGGCGCCCGAACAGGGACA-3 and 5-TCGGGCGC-
CACTGCTAGAGA-3, respectively. The quenched samples
were thenmixedwith an equal volumeof gel loading buffer, and
products were separated from substrates as described above.
The disappearance of substrate (20-mer) and the formation of
product (21-mer) were quantified using a Bio-Rad GS525
Molecular Imager (Bio-Rad). Data were fitted by non-linear
regression with Sigma Plot software (Systat Software, Inc., San
Jose, CA) using the appropriate equations (20). The apparent
burst rate constant (kobs) for each particular concentration of
dNTP was determined by fitting the time courses for the for-
mation of product (21-mer) using the following equation:
[21-mer]  A[1  exp(kobst)], where A represents the burst
amplitude. The turnover number (kpol) and apparent dissocia-
tion constant for dNTP (Kd) were then obtained by plotting the
apparent catalytic rates (kobs) against dNTP concentrations and
fitting the data with the following hyperbolic equation: kobs 
(kpol[dNTP])/([dNTP]  Kd). Catalytic efficiency was calcu-
lated as the ratio of turnover number over dissociation constant
([kpol/Kd]). Selectivity for natural dNTP versus ANP was calcu-
lated as the ratio of catalytic efficiency of dNTP over that of
ANP ([(kpol/Kd)dNTP/(kpol/Kd)ANP]). Resistance was calculated
as the ratio of selectivity of the mutant over that of WT
([(selectivity)Mutant/(selectivity)WT]).
Excision Assays—A 26-nucleotide DNA primer (P; 5-CCT-
GTTCGGGCGCCACTGCTAGAGAT-3) was 5-radiola-
beled with [-32P]ATP and chain-terminated with either
PMEO-DAPym-pp, (R)PMPA-pp, or PMEA-pp as reported
previously (19). This chain-terminated primer was then
annealed to a DNA template (5-CTCAGACCCTTTTAGTC-
AGAATGGAAATTCTCTAGCAGTGGCGCCCGAACAG-
GGACA-3). ATP-mediated excision assays were carried out by
first incubating 20 nM T/P with 3 mM ATP, 10 mM MgCl2, 1 M
dATP, and 10 M ddGTP in a buffer containing 50 mM Tris-HCl
(pH 7.5) and 50 mM KCl. Reactions were initiated by the addition
of 200 nM WT or mutant RT. Aliquots were removed at defined
times, quenchedwith sample loading buffer, and denatured at
95 °C for 10 min, and then the product was resolved from
substrate by denaturing polyacrylamide gel electrophoresis
and analyzed, as described above. Dead-end complex forma-
tion was evaluated using the same assay set-up described
above. However, the concentration of the next correct dNTP
(i.e. dATP) was varied from 0 to 100 M, and reactions were
quenched after 60 min.
Molecular Modeling—Molecular models were constructed
using the x-ray crystallographic coordinates for the RTT/
P(R)PMPA-pp ternary complex (21) (PDB, 1T05). PMEO-
DAPym-pp was docked into the DNA polymerization active
site, and energy minimization experiments were carried out
using Molecular Operating Environment (Chemical Com-
puting Group, Montreal, Quebec, Canada). Charges were
calculated using the Gasteiger method, and iterative minimi-
zations were carried out using the AMBER 99 forcefield until
the energy difference between iterations was 0.0001 kcal/
mol per Å.
TABLE 1
Inhibition of HIV-1 RT-mediated DNA synthesis by PMEO-DAPym-pp and other nucleoside analogs on homopolymeric T/Ps
IC50a
Poly(rC)/oligo(dG)
3HdGTP
Poly(rU)/oligo(dA)
3HdATP
Poly(rA)/oligo(dT)
3HdTTP
Poly(rI)/oligo(dC)
3HdCTP
MgCl2 MnCl2 MgCl2 MnCl2 MgCl2 MnCl2 MgCl2 MnCl2
M
PMEO-DAPym-pp 200 16	 3.3 NDb 0.26	 0.10 200 200 200 200
PMEA-pp 100 75	 21 ND 0.12	 0.06 100 100 100 100
ddATP 100 72	 13 ND 0.23	 0.17 100 100 100 100
ddTTP 100 100 ND 100 0.053	 0.011 0.072	 0.001 100 100
AZTTP 100 100 ND 67	 7 0.024	 0.020 0.006	 0.004 100 59	 7
a The 50% inhibitory concentration (M) required to inhibit the enzyme reaction by 50%. The concentration of MgCl2 or MnCl2 in the reaction mixture was 5 mM. Data are the
mean	 S.D. of two to three independent determinations.
bND, not detectable.
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RESULTS ANDDISCUSSION
Inhibition of HIV-1 RT-mediated DNA Synthesis by PMEO-
DAPym-pp in the Presence ofHomopolymeric T/Ps—The ability
of PMEO-DAPym-pp to inhibit HIV-1 RT-mediatedDNA syn-
thesis was first evaluated using four different homopolymeric
T/Ps (Table 1). PMEA-pp and the 2,3-dideoxynucleotide
derivatives ddATP, ddTTP, andAZT-TPwere included as con-
trols in these experiments. Reactions were carried out using
either MgCl2 or MnCl2 as the divalent metal ion. In general,
MgCl2-mediatedDNApolymerization reactions proceeded 10-
to 100-fold more efficiently than MnCl2-mediated reactions
when poly(rC)/oligo(dG), poly(rA)/oligo(dT), or poly(rI)/oligo
(dC) were used as the T/P substrate. By contrast, efficient DNA
synthesis on the poly(rU)/oligo(dA) T/P was only observed
when MnCl2 was used as the divalent metal ion (data not
shown). PMEO-DAPym-pp showed pronounced submicromo-
FIGURE 3. Double-reciprocal plots for HIV-1 RT inhibition by PMEO-DAPym-pp using poly(rU)/oligo(dA) and MnCl2-dATP or poly(rC)/oligo(dG) and
MnCl2-dGTP as substrates. The assay conditions are described under “Experimental Procedures.” PMEO-DAPym-pp was determined to be a competitive
inhibitor of dATP (A) anddGTP (B) bindinganda linearmixed-type inhibitor of poly(rU)/oligo(dA) (C) or poly(rC)/oligo(dG) (D) binding. TheKi valuesdetermined
from these experiments are provided in Table 2.
TABLE 2
Km- and Ki-values for PMEO-DAPym-pp and PMEA-pp against HIV-1 RT using homopolymeric T/Ps
TheKm andKi values (M)were calculated from the kinetic data in Fig. 3 using linear regression analysis. Data are themean	 S.D. of two to three independent experiments.
Inhibitor
Competing entity
Poly(rU)/oligo(dA) dATP Poly(rC)/oligo(dG) dGTP
Km Ki Km Ki Km Ki Km Ki
M
PMEO-DAPym-pp 1.2	 0.1 0.41	 0.10 16	 5 0.29	 0.22 17	 10 12	 2.2 2.7	 0.5 5.8	 1.2
PMEA-pp 1.2	 0.4 0.12	 0.05 10	 2 0.10	 0.06 17	 10 46	 1.0 3.0	 0.7 39	 5.7
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lar inhibitory activity (IC50  0.26 M), that was similar to
PMEA-pp (IC50 0.12 M) or ddATP (IC50 0.23 M), when
poly(rU)/oligo(dA) and MnCl2-dATP were used as substrates.
By contrast, 385- and 257-fold higher concentrations of ddTTP
and AZT-TP, respectively, were required to inhibit DNA syn-
thesis using the same substrates (Table 1). Interestingly,
whereas PMEO-DAPym-pp did not inhibit reactions on the
poly(rA)/oligo(dT) or poly(rI)/oligo(dC) T/P substrates at 200
M, the compound was found to exert modest inhibition
(IC50  16 M) when poly(rC)/oligo(dG) and MnCl2-dGTP
were used as substrates. By contrast, PMEA-pp and ddATP did
not show pronounced inhibitory activity (IC50 as high as 72–75
M) under similar assay conditions (Table 1). Interestingly, no
inhibition of DNA synthesis was observed at concentrations of
100MPMEO-DAPym-ppwhenMnCl2was replaced byMgCl2.
Additional studies demonstrated that PMEO-DAPym-pp acted
as a competitive inhibitor of MnCl2-[3H]dATP or MnCl2-
[3H]dGTP binding, and as a linear mixed-type inhibitor of
poly(rU)/oligo(dA) or poly(rC)/oligo(dG) binding (Fig. 3). The
Michaelis-Menten constants, Km and Ki, determined from
these experiments are provided in Table 2. Taken together,
these data demonstrate that HIV-1 RT recognizes and incorpo-
rates PMEO-DAPym-pp as an adenine nucleotide derivative.
The fact that PMEO-DAPym-pp was also weakly incorporated
by HIV-1 RT into the poly(rC)/oligo(dG) T/P substrates when
MnCl2 was used as the divalent
metal ion suggests that this nucleo-
tide might also base pair with cyto-
sine. Alternatively, it is well known
that nucleotide misincorporation is
more readily facilitated by MnCl2 in
comparison with MgCl2, because
MnCl2 can partially compensate for
the rate-limiting chemistry step that
governs misincorporation reactions
(22).The fact thatPMEO-DAPym-pp
incorporation is not observed oppo-
site cytosine in the more physiologi-
cally relevant heteropolymeric T/P
substrate might also suggest that this
result is an artifact inherent to the
homopolymeric T/P substrate.
Inhibition of HIV-1 RT-mediated
DNA Synthesis by PMEO-DA-
Pym-pp in the Presence of Hetero-
polymeric T/Ps—Wenext examined
the ability of PMEO-DAPym-pp to
inhibit HIV-1 RT-mediated DNA
polymerization on heteropolymeric
DNA/DNA and RNA/DNA T/Ps
with MgCl2 as the divalent metal
cation (Fig. 4). In these experiments,
(R)PMPA-pp and PMEA-pp were
included as controls. Consistent
with the studies described above, we
found that HIV-1 RT recognized
PMEO-DAPym-pp as a purine but
not a pyrimidine nucleotide analog
and incorporated it opposite to thymine in the DNA template
or uracil in the RNA template. As expected, its incorporation
resulted in chain termination of DNA synthesis. The concen-
tration of PMEO-DAPym-pp required to inhibit HIV-1 RT-
catalyzed DNA synthesis by 50% (IC50) was calculated to be 3.5
M and 15 M on the DNA/DNA and RNA/DNA template/
primer substrates, respectively. By comparison, the IC50 values
for (R)PMPA-pp and PMEA-pp were calculated to be 0.79 M
and 0.78 M for the DNA/DNA, and 1.83 M and 1.21 M for
the RNA/DNA T/P substrates, respectively. In these assays,
PMEO-DAPym-pp was not incorporated opposite to the alter-
native pyrimidine cytosine, even when MnCl2 was used as the
divalent metal ion (data not shown).
Pre-steady-state Incorporation of PMEO-DAPym-pp by WT,
K65R, K70E, and M184V HIV-1 RT—Pre-steady-state kinetic
analyses were carried out to elucidate, in detail, the interactions
between PMEO-DAPym-pp and the polymerase active site of
HIV-1 RT (Table 3). Because PMEO-DAPym-pp behaves as an
adenine nucleotide analog, we again included (R)PMPA-pp and
PMEA-pp as controls. In addition, we examined the activity of
PMEO-DAPym-pp against RTs containing the K65R and K70E
mutations that are associated with (R)PMPA and PMEA resis-
tance, respectively (23, 24). In addition, we investigated the
activity of PMEO-DAPym-pp against M184V containing
HIV-1 RT, because this mutation has been reported to confer
FIGURE 4. Incorporation of PMEO-DAPym-pp as an adenosine analog byWTHIV-1 RT in DNA/DNA (A) or
RNA/DNA (B) T/P. The sequences of the DNA/DNA and RNA/DNA T/P are indicated above each
autoradiogram.
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hypersusceptibility to (R)PMPA-pp in transient kinetic analy-
ses (29). The results (Table 3) show that the catalytic efficiency
of incorporation (kpol/Kd) of PMEO-DAPym-pp forWTHIV-1
RT is
2- to 3-fold less than the kpol/Kd values determined for
PMEA-pp or (R)PMPA-pp. This decrease in the kpol/Kd value
for PMEO-DAPym-pp (relative to PMEA-pp and (R)PMPA-
pp) is driven predominantly by a slower rate of nucleotide ana-
log incorporation (kpol) and not by a diminished binding affinity
(Kd) for the DNA polymerase active site of RT. As reported
previously, the catalytic efficiency of incorporation of
(R)PMPA-pp is decreased 12.4- and 2.5-fold by the K65R and
K70Emutations in RT (17, 18). Consistent with previously pub-
lished cross-resistance data (23, 24), both the K65R and K70E
mutations in HIV-1 RT also conferred resistance to PMEA-
pp. Similar to (R)PMPA-pp, this resistance was driven pri-
marily by a selective decrease in the rate of PMEA-pp incor-
poration (kpol) and not by a decrease in the nucleotide
binding affinity (Kd). Both the K65R and K70E mutations in
RT also conferred resistance to PMEO-DAPym-pp via a sim-
ilar mechanism (i.e. selective decrease in kpol). However,
PMEO-DAPym-pp displayed better incorporation activity
against K65R RT than (R)PMPA-pp. In this regard, a previ-
ous study reported that PMEO-DAPym exhibited better
antiviral activity (lower levels of phenotypic drug resistance)
against a panel of clinical virus isolates that contained mul-
tiple drug resistance mutations, including K65R, than did
either PMEA or (R)PMPA (15). Furthermore, these data also
highlight that subtle changes in the side chains and identity
of the base part have a marked impact on the ANP antiviral
activity spectrum. Finally, our data also show that HIV-1 RT
containingM184V remains sensitive to inhibition by PMEO-
DAPym-pp, PMEA-pp, and (R)PMPA-pp. In this regard,
Deval et al. previously reported that M184V HIV-1 RT
showed increased susceptibility to (R)PMPA-pp in pre-
steady-state kinetic assays (29). In this study, the
(R)PMPA-pp hypersusceptibility was primarily driven by a
decreased catalytic efficiency for dATP (but not (R)PMPA-
pp) incorporation by M184V HIV-1 RT. By contrast, we did
not observe (R)PMPA-pp hypersusceptibility by M184V
HIV-1 RT: the catalytic efficiency of dATP incorporation
(kpol/Kd) by M184V RT was not significantly decreased rela-
tive to the WT enzyme (Table 4). The different results
obtained in these two studies might be due to sequence-
specific differences resulting from the different T/P sub-
strates used.
ATP-mediated Excision of PMEO-DAPym by WT and
Mutant HIV-1 RT—HIV-1 RT has the intrinsic ability to
rescue DNA synthesis from a blocked primer by ATP-medi-
ated phosphorolytic excision of the DNA chain-terminating
nucleotide (25). This ATP-mediated excision activity of
HIV-1 RT is selectively increased by thymidine analog muta-
tions (TAMs) (26, 27) but can be diminished by other muta-
tions, including K65R and K70E (17, 18). Accordingly, we
next investigated the ability of WT, K65R, K70E, and TAM-
TABLE 3
Pre-steady state kinetic incorporation values for WT and drug-resistant HIV-1 RT
dATP ANP Selectivitya Resistancebkpol Kd kpol/Kd kpol Kd kpol/Kd
s1 M M1 s1 s1 M M1 s1
PMEO-DAPym-pp
WT 24.4	 3.9c 3.2	 1.2 7.6 1.1	 0.3 2.3	 1.1 0.49 15.5
K65R 12.6	 1.9 3.2	 0.7 4.0 0.21	 0.04 3.5	 2.1 0.06 65.8 4.2
K70E 18.0	 2.8 3.3	 0.9 5.5 0.18	 0.01 2.3	 0.6 0.08 69.3 4.5
M184V 14.8	 6.4 2.5	 0.8 5.9 1.2	 0.08 4.3	 0.2 0.27 21.7 1.4
(R)PMPA-pp
WT 24.4	 3.9 3.2	 1.2 7.6 6.16	 1.0 4.3	 1.0 1.44 5.3
K65R 12.6	 1.9 3.2	 0.7 4.0 0.45	 0.06 7.3	 2.7 0.06 65.8 12.4
K70E 18.0	 2.8 3.3	 0.9 5.5 2.1	 0.1 5.1	 1.5 0.41 13.5 2.5
M184V 14.8	 6.4 2.5	 0.8 5.9 2.0	 0.9 2.6	 0.3 0.76 7.8 1.5
PMEA-pp
WT 24.4	 3.9 3.2	 1.2 7.6 5.1	 1.3 4.0	 1.5 1.26 6.0
K65R 12.6	 1.9 3.2	 0.7 4.0 0.52	 0.28 4.2	 1.8 0.12 32.9 5.5
K70E 18.0	 2.8 3.3	 0.9 5.5 2.5	 0.5 4.3	 1.4 0.59 9.39 1.6
M184V 14.8	 6.4 2.5	 0.8 5.9 1.95	 0.6 3.4	 1.3 0.57 10.3 1.7
a Selectivity is (kpol/Kd)dNTP/(kpol/Kd)ANP.
b Resistance (n-fold) is selectivitymutant/selectivityWT.
c Values represent mean	 S.D. of three independent experiments.
TABLE 4
Excision rates and dead-end complex formation byWT andmutant RT
Excision ratea IC50 for DEC formationb
(R)PMPA PMEA PMEO-DAPym (R)PMPA PMEA PMEO-DAPym
min1 min1 min1 M M M
WT 0.024	 0.00 0.014	 0.00 0.025	 0.01 30.1	 6.5 14.7	 2.7 14.6	 1.8
TAM67c 0.088	 0.02 (3.7)d 0.043	 0.01 (3.1) 0.080	 0.01 (3.2) 79.0	 4.5 65.9	 1.6 67.4	 4.6
TAM41e 0.086	 0.02 (3.6) 0.030	 0.01 (2.1) 0.065	 0.01 (2.6) 78.3	 5.4 50.0	 9.0 55.6	 7.5
a Values represent mean	 S.D. from two independent experiments.
b Values represent mean	 S.D. from three independent experiments.
c TAM67: D67N/K70R/T215F/K219Q.
d Values in parentheses indicate -fold change compared to WT RT.
e TAM41: M41L/L210W/T215Y.
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containing RT to excise PMEO-DAPym from a DNA chain-
terminated T/P. Two RT enzymes that contained different
patterns of TAMs (e.g. M41L/L210W/T215Y (TAM41) and
D67N/K70R/T215F/K219Q (TAM67)) were included in this
study. In addition, (R)PMPA- and PMEA-chain-terminated
DNAs were included as controls. The results (Fig. 5 and
Table 4) demonstrate that, in comparison with the WT
enzyme, both TAM41 and TAM67 HIV-1 RT exhibited
increased capacities to excise all three ANPs. However, the
excision of PMEA and PMEO-DAPym by TAM41 RT
occurred less efficiently than that of (R)PMPA. In contrast to
the RTs containing TAMs, the mutant K70E and K65R RT
enzymes exhibited poor excision activity that was indepen-
dent of the DNA chain-terminating nucleotide analog. Pre-
vious studies have shown that the next complementary
nucleotide can inhibit ATP-mediated chain terminator
removal (28). To determine the magnitude and nature of this
inhibition against PMEO-DAPymp, PMEA, and (R)PMPA,
we determined the 50% inhibitory concentrations (IC50) of
the next complementary nucleotide for the ATP-dependent
removal of each of the acyclic nucleoside phosphonate ana-
logs. The results (Table 4) show
that the inhibitory concentrations
of the next complementary dNTP
were found to be somewhat higher
for (R)PMPA compared with
either PMEA and PMEO-DAPym.
Taken together, these data suggest
that PMEO-DAPym is a less effi-
cient substrate for ATP-mediated
excision than (R)PMPA. These
findings may suggest that PMEO-
DAPym may eventually be supe-
rior to (R)PMPA as an antiretrovi-
ral drug in respect of phenotypic
drug resistance levels.
Molecular Modeling—A molec-
ular model of PMEO-DAPym-pp
bound at the DNA polymerase
active site of HIV-1 RT was gener-
ated by docking this compound
into the RTT/P(R)PMPA-pp
structure (PDB coordinate 1T05).
The model (Fig. 6A) shows that
PMEO-DAPym-pp can reside in
the DNA polymerase active site of
RT without significant perturba-
tion of its key residues (e.g. Lys65,
Arg72, Asp110, Tyr115, Asp185,
Asp186, and Gln151). In fact, over-
lay of the RTT/P(R)PMPA-pp
structure with our model suggests
that the active site architecture is
essentially unchanged, including
the YMDD motif that is essential
for catalysis (Fig. 6B). In addition,
the model shows that the C-6
phosphonate linkage allows the
pyrimidine ring in PMEO-DAPym to mimic an open incom-
plete purine ring that allows the canonical Watson-Crick
base pairing to be maintained.
Conclusions—In the present study, we demonstrate that
HIV-1 RT efficiently recognizes PMEO-DAPym-pp as a
purine (e.g. adenine) nucleotide derivative but not as a
pyrimidine nucleotide derivative. Ourmodeling and docking
studies in HIV-1 RT confirm the similarities between
PMEO-DAPym-pp and (R)PMPA-pp in terms of a mimetic
of an incomplete purine ring (DAPym) and are in full agree-
ment with the obtained kinetic data. This is a striking obser-
vation and the first demonstration that a pyrimidine nucle-
otide analog can be unambiguously recognized as an adenine
nucleotide derivative for both binding and incorporation
into the growing DNA chain by HIV-1 RT. Moreover, such
wrongly incorporated nucleotide derivative shows a lesser
efficient increase of excision from the terminated DNA
chain by mutant RTs than (R)PMPA. Such drugs maymake it
more difficult to the virus to escape drug pressure and may
eventually exert lower phenotypic drug resistance levels, as
FIGURE 5. Autoradiograms (A) and rates (B) for ATP-mediated excision of PMEO-DAPym, (R)PMPA,
and PMEA by WT and mutant HIV-1 RT. For B, data represent the mean 	 S.D. of two independent
experiments.
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experimentally already shown in cell culture when PMEO-
DAPym is compared with (R)PMPA (15).
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FIGURE 6. A model of PMEO-DAPym-pp bound at the DNA polymerase
active site of HIV-1 RT (A). PMEO-DAPym-pp was docked into the RTT/
P(R)PMPA-pp ternary structure (PDB coordinate 1T05). No significant disrup-
tion of the active site residues was observed. In B, an overlay of the RTT/
PPMEO-DAPym-pp model with the RTT/P(R)PMPA-pp structure dem-
onstrates that PMEO-DAPym-pp mimics an incomplete purine ring and
allows canonical Watson-Crick base pairing.
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